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IntroductIon
Immune responses, whether harmful or beneficial, are com-
monly assessed by taking blood samples and measuring the 
levels of circulating lymphocytes and their products, such as 
cytokines and immunoglobulins. In humans, access to tumor 
tissue, spleen, and lymph nodes requires surgical interventions 
such as biopsies or sampling at autopsy, invasive methods dif-
ficult to apply on a large scale. Mouse models that are often 
used for preclinical studies related to cancer immunology pre-
dominantly rely on euthanasia and examination at necropsy of 
organs and tissues of interest, which does not provide longitu-
dinal information for therapeutic responses. For these reasons, 
accurate assessments of immune responses remain a challenge.
The field of immuno-oncology has expanded rapidly 
with the approval of new antibody therapies that target im-
mune checkpoints and of cell-based therapies that use chime-
ric antigen receptor–expressing T cells (CAR-T cells; Dougan 
and Dranoff, 2009; Vesely et al., 2011; Baumeister et al., 2016; 
Holzinger et al., 2016). For certain cancers such as melanoma 
and non-small-cell lung cancer, immunotherapy has revolu-
tionized clinical treatment and even produced cures (Dougan 
and Dranoff, 2009; Vesely et al., 2011; Larkin et al., 2015; Bau-
meister et al., 2016), but the failure of most patients to achieve 
long-term remission, even in these treatable types of cancer, 
remains an important obstacle, particularly given the severity 
of the side effects often associated with checkpoint blockade 
(Baumeister et al., 2016; Kourie and Klastersky, 2016). To fol-
low and visualize immune responses longitudinally and pre-
dict outcome would thus be highly desirable. It may then be 
possible to stratify patients into responders and nonrespond-
ers during the course of immunotherapy, such that decisions 
to continue or terminate therapy might be refined in case 
of an equivocal response. In humans, the presence in biopsy 
specimens of tumor-infiltrating CD8 T cells, rather than tu-
mor-surrounding CD8 T cells, correlates with a favorable re-
Immunotherapy using checkpoint-blocking antibodies against targets such as ctLA-4 and Pd-1 can cure melanoma and non–
small cell lung cancer in a subset of patients. the presence of cd8 t cells in the tumor correlates with improved survival. We 
show that immuno–positron emission tomography (immuno-PEt) can visualize tumors by detecting infiltrating lymphocytes 
and, through longitudinal observation of individual animals, distinguish responding tumors from those that do not respond to 
therapy. We used 89Zr-labeled PEGylated single-domain antibody fragments (VHHs) specific for cd8 to track the presence of 
intratumoral cd8+ t cells in the immunotherapy-susceptible B16 melanoma model in response to checkpoint blockade. A 
89Zr-labeled PEGylated anti-cd8 VHH detected thymus and secondary lymphoid structures as well as intratumoral cd8 t cells. 
Animals that responded to ctLA-4 therapy showed a homogeneous distribution of the anti-cd8 PEt signal throughout the 
tumor, whereas more heterogeneous infiltration of cd8 t cells correlated with faster tumor growth and worse responses. to 
support the validity of these observations, we used two different transplantable breast cancer models, yielding results that 
conformed with predictions based on the antimelanoma response. It may thus be possible to use immuno-PEt and monitor 
antitumor immune responses as a prognostic tool to predict patient responses to checkpoint therapies.
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sponse to checkpoint blockade (Sato et al., 2005; Kawai et al., 
2008; Yamada et al., 2010).
Positron emission tomography (PET) using labeled 
antibodies or antibody fragments (immuno-PET) may 
achieve some of these goals (Weissleder et al., 2016). Im-
muno-PET can detect CD8 T cells in living mice, either 
by using retrovirus-transduced human T cells and detec-
tion via the murinized TCRβ constant domain with an 
89Zr-labeled F(ab')2 fragment (Mall et al., 2016) or, alter-
natively, by using isotopically labeled ∼55-kD anti-CD8 
diabodies, constructed by fusing two identical single-chain 
variable fragments (scFvs; Tavaré et al., 2016). Anti–mouse 
CD8 diabodies can detect CD8 T cells not only in lym-
phoid organs but also in a transplanted tumor after immu-
notherapy with 4-1BB or anti–PD-L1 checkpoint-blocking 
antibodies (Tavaré et al., 2016). However, the key question 
that remains is whether it is possible to predict the outcome 
of checkpoint blockade therapy, based not only on the pres-
ence of CD8 T cells but also on their numbers, intratu-
moral distribution and perhaps most importantly dynamic 
changes in these parameters over time. We demonstrate that 
immuno-PET can achieve this goal.
To accomplish noninvasive monitoring of the distri-
bution of CD8 T cells, we made use of the smallest anti-
body-derived format that retains antigen-binding capability, 
the variable region segment of camelid heavy chain-only anti-
bodies, also referred to as VHHs, nanobodies, or single-domain 
antibodies (Fig. 1 A; Saerens and Muyldermans, 2012). These 
fragments are ∼15 kD in size and readily lend themselves 
to sortase-catalyzed enzymatic modifications for a variety of 
purposes, including the installation of radioisotopes for PET 
imaging (Rashidian et al., 2015a,b; Van Elssen et al., 2017).
rEsuLts And dIscussIon
Generation of an anti-cd8 single-domain antibody 
fragment and its characterization
Mononuclear cells from a llama immunized with mouse 
CD8αβ heterodimer stabilized via a C-terminal leucine 
zipper were used as a source of RNA to construct a VHH 
phage display library; this yielded several VHH sequences that 
bound the mouse CD8 marker with nanomolar affinity. We 
used one of them, VHH-X118, (kD ∼0.9 nM; Fig. S1) for 
further characterization and as an imaging agent to track the 
distribution of CD8 T cells.
VHH-X118 was engineered to contain a sortase rec-
ognition tag, LPE TG, near its C terminus. Sortase, a trans-
peptidase, recognizes the LPX TG motif and cleaves the bond 
between the threonine and glycine residues to form a thio-
ester intermediate. A triglycine-functionalized substrate can 
then replace the enzyme to yield a protein-LPXT-GGG-R 
product, where R can be any chemical moiety of inter-
est (Fig.  1  B; Guimaraes et al., 2013). VHH-X118 was 
site-specifically labeled with Alexa Fluor 647 using sortase 
(Fig.  1  B). LC-MS and SDS-PAGE analysis confirmed la-
beling (Fig. 1, C and D).
Freshly prepared splenocytes and lymph node cells were 
stained with Alexa647-labeled VHH-X118 and costained 
with fluorescent antibodies against the CD45, CD3, CD19, 
and CD4 markers to identify the relevant lymphocyte 
subsets. Cytofluorimetry showed that VHH-X118 in-
deed stained CD8 T cells (Fig. 1 E). Cells did costain with 
a commercial anti-CD8β antibody. When costained with a 
commercial anti-CD8α antibody, VHH-X118 effectively 
competed for binding (Fig. S1), showing that VHH-X118 
binds to the CD8α chain.
Improving anti-cd8 VHH for immuno-PEt by PEGylation
Using sortase, we installed desferrioxamine (DFO) at the C 
terminus of VHH-X118 to enable chelation of 89zirconium 
(89Zr; t1/2 = 3.27 d) as a PET tracer (Fig. S2). We performed 
PET imaging on C57BL/6 mice with 89Zr-VHH-X118 and 
observed robust and specific accumulation of label in lym-
phoid organs (Fig. 2 and Video 1). Uptake of 89Zr-VHH-X118 
in the kidney was high, a pattern commonly seen for labeled 
VHHs (Vegt et al., 2010; D’Huyvetter et al., 2014).
Accumulation of VHHs, scFvs, and similar antibody frag-
ments in kidneys and other organs of elimination, such as liver 
and intestines, produces suboptimal signal-to-noise ratios and 
complicates the straightforward analysis of tumors growing at 
or near these anatomical locations (Knowles et al., 2014; Wu, 
2014; Rashidian et al., 2015a). Translation of these smaller an-
tibody formats to clinical use may benefit from addressing this 
particular drawback. We reasoned that the hydrophilic nature 
of a polyethylene glycol (PEG) substituent might reduce ac-
cumulation of 89Zr-labeled VHH in organs of elimination (Li 
et al., 2010, 2011). We therefore explored sortase-catalyzed 
PEGylation of 89Zr-labeled VHHs as a means of improving 
image quality. Site-specific modification of a VHH with PEG 
in a sortase reaction should leave its antigen-binding site un-
obstructed, as the PEG modification will be located at a site 
opposite to the complementarity-determining regions of 
the VHH (Rashidian et al., 2016). By extending circulatory 
half-life, PEGylation would further increase the probability of 
a VHH finding its target in the proper orientation. We there-
fore designed VHHs modified with PEG moieties that varied 
in molecular weight from 5 to 20 kD to determine the op-
timal size of a PEG substituent consistent with an acceptable 
signal-to-noise ratio. VHHs with modifications in this size 
range should still be cleared reasonably efficiently by glomer-
ular filtration (cutoff <60 kD).
We synthesized a biorthogonal sortase substrate con-
taining both an azide click handle and the metal chelator 
DFO (Fig.  2, A and B). The click handle allowed covalent 
attachment of dibenzylcyclooctyne-substituted PEG moi-
eties of 5, 10, and 20 kD, respectively, all of which showed 
improved lymph node staining and decreased kidney uptake 
compared with non-PEGylated VHH-X118 (Fig. 2, C–F; Fig. 
S2; and Videos 2, 3, 4, and 5). At 24 h postinjection (p.i.), im-
ages obtained for the 20-kD PEGylated VHH-X118 showed 
crisp staining of lymphoid organs, including the mesenteric 
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lymph node, with much reduced accumulation in the kidneys 
(Fig. 2 F). It was therefore used for all further studies.
specificity and sensitivity of the anti-cd8 PEt signal
To establish specificity of staining with 89Zr-labeled 20-kD 
PEGylated VHH-X118, we used RAG-KO mice, which lack 
B and T cells altogether but continue to form CD8+ DCs 
(Mombaerts et al., 1992). With the exception of a weak sig-
nal in the spleen, likely from these CD8+ DCs, there was al-
most no accumulation of label in lymphoid organs (Fig. 2 G 
and Video  6), demonstrating specificity of the signal ob-
served in wild-type animals.
We also imaged OT-I-RAG KO TCR transgenic mice, 
in which all T cells are CD8+ (Hogquist et al., 1994), and we 
observed a pattern of label accumulation comparable to that 
seen in wild-type mice, with the exception of a strong sig-
nal for an enlarged mesenteric lymph node, a known feature 
of this particular transgenic model (Fig. S3 and Video 7). To 
estimate the number of CD8 T cells that could be detected 
using 89Zr-PEGylated VHH-X118, we excised lymph nodes 
Figure 1. characterization of cd8-specific single domain antibody. (A) Represen-
tation of a camelid heavy-chain-only antibody and a conventional IgG. The VHH portion 
is indicated. (B) Site-specific labeling of VHHs using sortase. (C and D) characteriza-
tion of X118-VHH and Alexa647-labeled X118-VHH, where SDS-PAGE (C) and LC-MS (D) 
analysis confirming the identity of the final products (lane 1, marker; lane 2, VHH-X118; 
lane 3, VHH-X118-Alexa647). (E) FACS analysis of splenocytes and lymph nodes gated 
on CD45+CD19−CD3+ cells confirming that X118-VHH stains CD8+ cells. Results are rep-
resentative of three to four experiments with similar results.
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and spleen and enumerated CD8 T cells per milligram wet 
weight by cytofluorometry. Lymph nodes contained ∼%16 
CD8 T cells, with ∼100,000 CD8 T cells per milligram wet 
weight. When the amount of radioactivity accumulated per 
unit weight of muscle was considered to represent the non-
specific background signal and was set at unity, we found >15 
Figure 2. 89Zr-labeled PEGylated anti-cd8 VHH detects cd8 t cells. (A) Structure of the biorthogonal sortase substrate. The azide functionality allows 
installation of PEG groups, and the DFO chelator is used to install 89Zr for PET imaging. (B) Schematic representation of preparing PEGylated 89Zr-labeled 
VHHs for PET imaging. (C–G and C-II–G-II) PET-CT images of anti-CD8 89Zr-labeled X118-VHH with and without different-size PEG functionalities in 
wild-type C57BL/6 and RAG-KO mice (n = 3 for each experiment). Images were acquired 24 h p.i. of radiolabeled VHHs. (C-II–G-II, top) Whole-body maxi-
mum intensity projections. (C-II–G-II, bottom) Transverse PET-CT images of cross sections through the spleen, showing specific staining and a reduction in 
accumulation of label in the kidney with increasing PEG size. (H) Characterization of functionalized VHHs. LC-MS analysis confirms formation of X118-DFO 
and X118-DFO-azide. (I) Biodistribution of anti-CD8 X118-VHH with and without different-size PEGs 24 h p.i. (n = 3 for each cohort). Error bars repre-
sent standard deviation.
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times more label accumulated in the brachial lymph node 
(Fig. 2 I). Hence, assuming as acceptable a minimal ratio of 
signal-to-background of 3, we could detect ∼20,000 CD8 T 
cells per milligram in a typical lymphoid organ. An increase 
in PET acquisition time and in injected dose is likely to fur-
ther improve sensitivity.
detecting tumors by immuno-PEt of infiltrated cd8 t cells
We next used 89Zr-PEGylated VHH-X118 to image tumors 
and determine its performance in detecting intratumoral 
CD8 T cells. C57BL/6 mice were implanted with B16 mel-
anoma cells and imaged with 89Zr-PEGylated-VHH-X118. 
Images acquired 24  h p.i. showed the presence of CD8 T 
cells in lymphoid organs as well as in and around the tumor 
(Fig. 3 A and Video 8). We next imaged WT B6 mice bear-
ing Panc02 tumors, a mouse pancreatic cancer cell line. It 
serves as a suitable model to establish the ability of VHHs to 
penetrate other tumor types (Rashidian et al., 2015b). Mice 
bearing heterotopically transplanted Panc02 tumors were 
imaged using 89Zr-PEGylated VHH-X118. Images acquired 
24 and 48  h p.i. showed CD8 T cells in lymphoid organs 
and infiltrating the tumor (Fig. 3, B and C; and Videos 9 and 
10). FACS analysis on tumor-infiltrating lymphocytes in this 
model confirmed the presence of CD8 T cells (Fig.  3  G). 
Not only did the PEGylated VHH penetrate the tumor, but 
cross-sections of the tumor also provided precise positional 
information (Fig. 3, D and E). We concluded that, with this 
level of resolution, we should be able to distinguish infiltra-
tion into a tumor from a distribution more peripheral to an 
island of neoplastic cells.
Monitoring the dynamics of cd8 t cells in  
response to therapy
To track the antitumor CD8 T cell response to checkpoint 
blockade, we used the B16 mouse melanoma model in con-
junction with B16 GVAX (Dranoff et al., 1993; Curran et 
Figure 3. Anti-cd8 89Zr-labeled PEG20-X118-VHH detects lymphoid organs and tumor-infiltrating cd8+ lymphocytes. (A and B) PET-CT images 
of tumor-bearing mice (A, B16 tumor; B, Panc02 tumor) injected with 89Zr-PEGylated VHH (n = 3 for each experiment). (C) Enlarged view of the tumor 
and draining lymph nodes. (D) A cross-section of the tumor shows the intratumoral distribution of infiltrated CD8+ T cells. (E) Enlarged view 2D and 3D 
representation of the cross section in D shows CD8+ T cells deep inside the tumor. (F) Biodistribution of PET signals in different organs and in the tumors. 
Error bars represent standard deviation. (G) Flow cytometry analysis on the Panc02-infiltrating immune cells confirmed infiltration by CD8+ T cells (n = 3).
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al., 2010; Sockolosky et al., 2016). In this model, coadminis-
tration of B16 together with irradiated B16 cells transfected 
with GM-CSF allows the tumors to grow, albeit at a reduced 
rate when compared with the behavior of control B16 tu-
mors implanted alone in their syngeneic C57BL/6 hosts 
(Dranoff et al., 1993; Sockolosky et al., 2016). When used as 
adjuvant therapy, GVAX, a lethally irradiated GM-CSF–se-
creting whole-cell melanoma vaccine, improves the antitu-
mor response. Treatment of animals having received the B16/
GVAX combination with an anti-CTLA4 antibody, adminis-
tered immediately after tumor implantation, mostly results in 
a complete response to therapy (Quezada et al., 2006; Cur-
ran et al., 2010). Instead, we started treatment 7 d after im-
plantation, a setting in which treatment with anti–CTLA-4 
leads to early regression in only a subset of animals (∼15%). 
The remainder of the cohort exhibited a wide spectrum of 
responses, with variable survival rates (Curran et al., 2010). 
Even so, every mouse that received anti-CTLA4 showed 
slower tumor growth compared with the untreated controls. 
Median survival for the cohort that received no treatment 
was ∼18 d (n = 5), whereas the cohorts with weak partial re-
sponses and strong partial responses exhibited median survival 
times of ∼40 d and >50 d, respectively (n = 15).
Having established conditions that would lead to vari-
able responses to CTLA-4 therapy, we tested whether intra-
tumoral distribution and evolution of CD8 T cell numbers 
over time correlated with a therapeutic response in individual 
mice. Immuno-PET is uniquely suited to address these ques-
tions, as no longitudinal noninvasive assessment of the efficacy 
of antitumor immunotherapy has been possible until now. We 
inoculated 20 C57BL/6 mice with B16 and B16 GVAX. A 
week later, all mice carried palpable tumors of similar size 
(∼3–5 mm in diameter). We randomized and assigned 15 an-
imals to anti-CTLA4 treatment, and five animals served as 
untreated controls. Each animal was then subjected to PET 
computed tomography (CT) using radiolabeled 20-kD PE-
Gylated VHH-X118 at four different time points (9, 16, 23, 
and 30 d after inoculation) to monitor tumor growth or re-
gression and to evaluate CD8 T cell infiltration (Fig. 4 A).
After delineating the outline of the tumor based on 
CT images, we determined the amount of label per voxel to 
determine more accurately the distribution of CD8 T cells 
throughout the tumor (Fig. 4, B, E, and F). As an objective 
measure of homogeneous versus heterogeneous distribu-
tion of CD8 T cells, we created random transects through 
the quantified PET images for each tumor and plotted the 
first derivative of the function thus obtained. We examined 
the plots for the presence of either a single maximum or for 
several local maxima. For the latter, the first derivative shows 
more than one zero, whereas the former shows a single zero 
at the position of maximum signal intensity (Fig. 4, E and F). 
Quantitation of the PET signals for each tumor shows that 
the critical parameter relevant for prognosis is the distribu-
tion of CD8+ T cells, independent of PET signal strength (P 
= 0.035; Fig. S4). We then asked whether these distributions 
had value in predicting the responses to anti-CTLA4 treat-
ment. In those tumors in which the CD8 PET signal was 
homogeneously distributed, with a single cluster of CD8 T 
cells throughout the tumor, mice continued to respond and 
tumors failed to increase in size or did so very slowly. In con-
trast, in tumor-bearing hosts with a more heterogeneous dis-
tribution of the CD8 PET signal (with two or more clusters 
of CD8 T cells), tumors grew faster and mice showed worse 
survival (Fig. 4, C–F; and Fig. S4).
using the identified patterns of responses to 
predict the outcome of therapy
To see whether our observations had more general applica-
bility, we performed similar experiments using mouse mam-
mary tumor cells to explore a possible correlation between 
CD8 T cell infiltration and response to anti-CTLA4 treat-
ment. We used a carcinoma isolated from the widely used 
MMTV-PyMT transgenic mouse model (Guy et al., 1992). 
These tumors are phenotypically heterogeneous with respect 
to epithelial and mesenchymal sectors. Therefore, to assess the 
differences in immune cell recruitment associated with the 
more epithelial- or mesenchymal-like carcinoma cells, we 
sorted the neoplastic cells based on the expression of an ep-
ithelial cell adhesion marker (Epcam) to obtain Epcam-high 
and Epcam-low cell populations. The different sorted sub-
populations of carcinoma cells were then each implanted 
into syngeneic hosts. Tumors arising from Epcam-high carci-
noma cells gave rise to well-differentiated adenocarcinomas, 
whereas those arising from the Epcam-low carcinoma cells 
produced poorly differentiated sarcomatoid tumors (unpub-
lished data). Two weeks after implantation of either neoplastic 
Epcam-high or Epcam-low cells, we performed PET imaging 
using 89Zr-PEGylated VHH-X118 to assess the distribution 
of CD8 T cells. Although both types of tumor showed CD8 
T cell infiltrates, the Epcam-high, well-differentiated tumors 
showed a homogenous distribution of CD8 T cells, whereas 
the poorly differentiated, more mesenchymal Epcam-low 
tumors showed a more heterogeneous distribution, with 
clusters of CD8 T cells scattered throughout the tumor (n 
= 3 for each cohort; Fig. 5, A–D). To confirm the specificity 
of our PET-CT findings, we imaged a set of animals with 
Epcam-high and Epcam-low tumors using 89Zr-PEGylated 
VHH-X118, excised the imaged tumors, and then exam-
ined these by immunohistochemistry. As predicted by the 
89Zr-PEGylated VHH-X118 PET-CT, Epcam-high tumors 
showed robust CD8 infiltrates into the tumor core, whereas 
Epcam-low tumors showed minimal CD8 infiltrates that 
were clustered around the tumor periphery (n = 5 for each 
cohort; Fig. 6). These results prompted us to ask whether the 
observed intratumoral distributions, similar to the B16 model 
characterized above, might have predictive value for the re-
sponse to checkpoint blockade.
Accordingly, we inoculated 20 individual wild-type B6 
mice with one million Epcam-high or Epcam-low cells and 
then randomly divided each cohort into two subgroups to 
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Figure 4. dynamics of cd8 t cell response and characterization of response patterns to immunotherapy. (A) C57BL/6 mice were inoculated with 
B16 melanoma cells and GVAX simultaneously. Treatment with anti-CTLA4 (clone 9H10) started 1 wk after inoculation to produce a heterogeneous re-
sponse. Mice received therapy and were subjected to PET imaging according to the schedule shown in scheme A. (B) PET-CT images of a B6 mouse, injected 
with 89Zr-PEG20-VHH X118, 9 d after inoculation of the tumor. (left) PET-CT maximum intensity projection of the mouse. (middle and right) A coronal 
cross section CT (middle) or PET-CT (right) image of the mouse. The images are taken through a cross section of the tumor. The box shows the tumor. (C) 
Mean growth of the tumor in the two cohorts, with or without therapy. Every mouse receiving therapy showed some level of response compared with the 
untreated cohort, albeit with significant heterogeneity, as evident from the standard deviations. Error bars represent standard deviation. (D) Comparison 
of the growth of tumors in two mice receiving therapy with a strong or a partial response. (E and F) for animals that received CTLA4 therapy, PET images 
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receive either anti-CTLA4 (clone 9H10, 200 µg, two times 
per week for 20 d) or no treatment (n = 5 for each group). 
Although the well-differentiated, more epithelial tumors 
with homogenous CD8 T cell distribution responded to 
anti-CTLA4 treatment, the poorly differentiated, more mes-
enchymal tumors with heterodisperse CD8 T cell distribu-
tion did not, as would be predicted based on the PET results 
(Fig. 5, E and F). The outcomes of CTLA4 treatment in the 
two tumor models therefore suggested that immuno-PET 
might be useful as a predictor of the response. A homoge-
neous distribution of CD8 T cells could, on its own, serve as 
an accurate biomarker of future response to anti-checkpoint 
therapy. These results agree well with immunohistological 
analysis of human biopsy specimens taken from patients re-
ceiving immunotherapy with checkpoint inhibitors, where 
nonresponding lesions show a peripheral distribution of 
CD8 T cells and responders show clear signs of CD8 T cells 
that penetrate the tumor (Sato et al., 2005; Kawai et al., 
2008; Yamada et al., 2010).
Invasive procedures such as biopsies cannot provide this 
type of global information for an entire tumor mass or its 
metastases and may yield less reliable or even misleading data 
when correlating immune cell infiltration status with the out-
come of immunotherapy. In some instances, a lesion may be 
heavily infiltrated with immune cells. It may therefore present 
as an increase in mass in CT scans and be mistaken for an 
increase in tumor size. Indeed, FDG-PET scans or CT im-
ages cannot distinguish between these two, inviting surgery 
to remove the lesions or even discontinuation of apparently 
ineffective treatment, when in fact, upon histopathological 
examination, these masses may turn out to be pure tertiary 
lymphoid structures containing essentially no neoplastic cells.
Earlier imaging procedures have been limited by sev-
eral factors. First, these studies only compared treated to un-
treated mice or, alternatively, examined tumors that expressed 
or lacked a target antigen of interest (McCracken et al., 2016); 
this does not recapitulate a typical clinical scenario. Second, 
tumors previously examined by others were dramatically 
different in size (McCracken et al., 2016), leaving open the 
possibility that the observed differences in intratumoral T 
cell distribution were a consequence rather than the cause of 
tumor growth and regression, the latter being due, for example, 
to central tumor necrosis. Finally, previously reported work 
has not followed T cell distribution longitudinally in individ-
ual mice and thus could not provide predictive information.
When assessing the distribution of intratumoral CD8 T 
cells as determined by PET, there are at least two important 
parameters to consider. First, tumors that continue to grow in 
the face of CTLA-4 blockade show heterodisperse accumu-
lation of the intratumoral PET CD8 signal over time. This is 
consistent with the notion that certain sectors of the tumor 
might experience a measure of immune privilege, exhaustion, 
or active immune suppression. Indeed, the absence of a CD8 
signal in certain portions of the tumor could result from local 
contraction of the CD8 pool or from a failure of CD8 T cells 
to reach that location at all, or it might reflect necrosis. Sec-
ond, as the nonresponding tumors grow, the focal accumula-
tion of this CD8 signal can change its relative position within 
the perimeter of the tumor. The local waning of the CD8 sig-
nal could reflect contraction of the antigen-experienced pool 
of CD8 T cells. The emergence of a CD8 signal at a location 
where previously there was none might result from a clonal 
burst in situ (e.g., when fresh CD8 T cells migrate into the 
tumor and then expand). Imaging CD8 T cells by PET thus 
clearly shows the dynamic nature of these CD8 T cell pop-
ulations in space and time. Our data cannot address whether 
the observed changes occur in response to alterations in the 
tumor or tumor microenvironment or simply reflect intrinsic 
properties of the T cell response. Sampling the pool of intra-
tumoral CD8 T cells by biopsy and characterizing them for 
TCR gene usage or specificity will provide a snapshot that is 
necessarily incomplete with respect to the past and future of 
the antitumor immune response.
The heterogeneous distribution of CD8 T cells may 
result from physical barriers, the presence of myeloid- 
derived suppressor cells releasing repulsive cues (Marigo et 
al., 2008; Movahedi et al., 2008), the failure of infiltrating 
CD8 T cells to respond to chemo-attractive signals, hypoxia 
and hypoxic signaling (McNamee et al., 2013), necrosis or 
some combination of these factors. We conclude that the 
ability to image an entire tumor environment noninvasively, 
making it possible to distinguish between the different dis-
tribution patterns of CD8 T cells, may serve as a valuable 
prognostic indicator of the success of checkpoint blockade 
therapy. In the future we need to be able to monitor the 
temporal dynamics of other immune cells, such as CD4 T 
cells and regulatory T cells, as well as visualize chemokines 
and cytokines to obtain a more accurate picture of the im-
mune landscape inside and around a tumor. In doing so, 
we may identify new mechanisms that drive the different 
of the tumors are shown. Tumors, as identified by CT, are delineated by the outline. The PET signals in the tumor are rendered as a heatmap. Below each 
image is the corresponding 3D graph, in which the z axis represents the strength of the PET signal (arbitrary units). On the right side of the PET images are 
shown PET signal intensities and their first derivatives (below each graph). Two (E) or three (F) different columns, as indicated with arrows, were picked, 
and graphs were drawn to show the local minima and maxima. The CD8 T cell signal was more homogenously distributed in mice with a strong response 
to CTLA4 treatment with no local minima throughout the tumor, whereas partial responders showed a more heterogeneous signal distribution with one 
or more local minima. Where relevant, areas with lower PET signals are indicated by arrows. The images show the dynamics of CD8 T cell throughout the 
tumors during 4 wk of imaging performed at 9, 16, 23, and 30 d after inoculation of the tumors. The images are representative of multiple experiments 
with similar results (Fig. S4; n = 15, P = 0.035).
 o
n
 February 23, 2018
jem.rupress.org
D
ow
nloaded from
 
2251JEM Vol. 214, No. 8
types of immune recruitment. Translation of this approach 
to the clinic may enable earlier identification of treatment 
response, help distinguish tumor progression from pseu-
do-progression, and make it possible to iteratively select 
new therapeutic interventions.
MAtErIALs And MEtHods
Animal studies were approved by the MIT Committee on 
Animal Care (CAC protocol number 1014-110-17).
Generation of the anti-cd8 VHHs
A llama was immunized in a weekly regimen six times with 
recombinant mouse CD8 (αβ mCD8-leucine zipper; AB 
Biosciences). VHH libraries were constructed from periph-
eral blood lymphocytes as described elsewhere (Pardon et 
al., 2014). Selections were done using a total of three rounds 
of panning performed on solid-phase immobilized antigen. 
Randomly selected colonies were analyzed by ELI SA for 
the presence of antigen-specific VHH in their periplasmic 
extracts. Sequence analysis of ELI SA-positive clones yielded 
52 candidates. Flow cytometry screening using mCD8 CHO 
transfectants with αβ 2M peptide (Holst et al., 2006) con-
firmed eight positives clones.
Analyzing binding affinity of lead VHHs.
Dissociation constants of anti–mouse CD8 were determined 
by biolayer interferometry (ForteBio Octet RED96 bio-
Figure 5. Predicting the response of immunotherapy in two different breast cancer models. WT C57BL/6 mice were inoculated with one million 
breast cancer cells (mesenchymal PB3 cells in A or epithelial PB2 cells in B). 2 wk p.i., mice were imaged by PET/CT using anti-CD8 89Zr-PEG20-VHH X118. 
(A) PET-CT images of the mesenchymal tumor-bearing mouse (n = 3); (left) PET/CT maximum intensity projection; (middle and right) coronal CT (middle) and 
PET-CT (right) images taken through a cross section of the tumor. The box outlines the tumor. (B) PET-CT images of the epithelial PB2 tumor-bearing mice 
(n = 3). (left) PET-CT maximum intensity projection. (middle and right) Coronal CT (middle) and PET-CT (right) images taken through a cross section of the 
tumor. (C and D) PET images of the tumors are shown. The PET signals in the tumor are rendered as a heat map. Below each image is the corresponding 3D 
graph, in which the z axis represents the strength of the PET signal (arbitrary units). The CD8 T cell signal was more homogenously distributed in epithelial 
tumors, whereas mesenchymal tumors showed a more heterogeneous signal distribution. Where relevant, areas with lower PET signals are indicated by 
arrows. On the right are graphs that show three randomly chosen transects (arrows) across each of the tumors, plotting the intensity of the PET signal along 
that transect. The first derivative of this function is shown below each graph to record the presence of local maxima. (E and F) Mean tumor growth with 
or without receiving therapy. Mice were injected subcutaneously with one million cells (mesenchymal cells in E or epithelial cells in F), followed by 200 µg 
anti-CTLA4 therapy (clone 9H10) three times per week for 20 d. The epithelial tumors showed a strong response, whereas the mesenchymal tumors did not 
(n = 5 for each cohort). Error bars represent standard deviation.
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layer interferometer) following the manufacturer’s protocol. 
In brief, recombinant mouse CD8αβ-leucine zipper fusion 
protein (AB Bioscience) was biotinylated (5:1 biotin/protein) 
using a Chromalink NHS-Biotin Protein Labeling System 
(Solulink) and immobilized on a streptavidin sensor. Sensors 
with immobilized CD8αβ were introduced to a solution 
containing 25–100 nM anti–mouse CD8 VHH. Binding was 
allowed to proceed for 90 s, followed by dissociation for 400 s. 
Unloaded biosensors and a nonspecific VHH were used for 
background subtraction. Local curve fitting analysis was per-
formed using ForteBio Data Analysis 8.1; dissociation con-
stants (KD) were calculated using the quotient of the observed 
association and dissociation rate constants (Fig. S1).
Enzymatic modification of the VHH
Penta mutant sortase A with an improved kcat, was used (Chen 
et al., 2011). 1-ml reaction mixtures contained 50 mM Tris-
HCl, pH 7.5, 10 mM CaCl2, 150 mM NaCl, 750 µM trigly-
cine-containing probe, 200 µM LPE TG-containing substrate, 
and 5 µM sortase (Witte et al., 2012; Theile et al., 2013). After 
incubation at 4°C with agitation for 30 min, reaction prod-
ucts were analyzed by LC-MS, with yields generally >80%. 
When the yield was below 80%, the reaction was allowed 
to proceed for an additional hour, with addition of sortase 
to 10 µM and triglycine-containing probe to 1 mM. The la-
beled VHH was purified by size exclusion chromatography 
in PBS or 50 mM Tris-HCl, pH 7.5. Ni-NTA beads were 
added to further purify the product followed by centrifu-
gation to remove sortase and any remaining unreacted His-
tagged substrate. The labeled protein was stored at −20°C and 
was stable for up to 6 mo.
Flow cytometry
All antibodies for flow cytometry were obtained from BD 
(CD3, CD8, CD19, CD4, and CD45). Cells, freshly prepared, 
were incubated with antibodies at appropriate dilutions for 
30 min at 4°C. Analyses were performed on a LSR-Fortessa 
flow cytometer (BD) and analyzed with CellQuest Pro 6.0 
software (BD) and FlowJo version 10 software (Tree Star).
synthesis of (Gly)3-dFo
The tetrapeptide GGGC was synthesized by standard solid 
phase peptide synthesis and was dissolved in 20 mM NaHCO3 
buffer (pH 8.3). Maleimide-DFO (from Macrocyclics) was 
dissolved in DMSO. The tetrapeptide GGGC was added and 
left to stir at room temperature for 30 min until LC-MS anal-
ysis indicated near-complete conversion to the product. The 
solution was filtered and purified by reverse-phase HPLC 
with a semipreparative column (C18 column, Gemini, 5 µm, 
10 × 250 mm; Phenomenex) at a flow rate of 5.0 ml/min; 
solvent A: 0.1% TFA in H2O, solvent B: 0.1% TFA in CH3CN. 
(G)3-DFO eluted at 70–75% solvent B. Fractions containing 
pure product were collected and lyophilized. LC-MS calcu-
lated for C41H71N12O15S [M+H]+ 1003.49, found 1003.70.
synthesis of (Gly)3-dFo-azide
The peptide GGG-PEG3-Cys-PEG3-Lys(azide) was synthe-
sized by standard solid-phase peptide synthesis and was dis-
solved in 20 mM NaHCO3 buffer, pH 8.3. Maleimide-DFO 
was dissolved in DMSO. The peptide was added to the DFO 
Figure 6. correlation of cd8 PEt images with immunostaining and 
histology of tumor sections. Wild-type C57BL/6 mice were inoculated 
with one million breast cancer cells (epithelial PB2 cells in A or mesen-
chymal PB3 cells in B). Mice were imaged 2 wk after inoculation by PET/CT 
using anti-CD8 89Zr-PEG20-VHH X118. (A and B) A transverse PET-CT image 
taken through a cross section of the tumor in mice bearing an epithelial 
(A) or mesenchymal (B) tumor (n = 5 for each cohort; one representative 
animal shown). (C) Hematoxylin and eosin (H&E) staining of tumor sam-
ples. (D) Immunohistochemistry (CD8+ cells) of paraffin-embedded, forma-
lin-fixed tumor sections shows homogeneous infiltration of CD8+ T cells 
into PB2 (epithelial tumor). For PB3 (mesenchymal tumor), CD8+ T cells 
remained mostly peripheral. Top and bottom panels are from the same 
sections at different magnifications. See supporting information in Fig. S5 
for full-size immunohistology and H&E images.
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solution and left to stir at room temperature for 30 min until 
LC-MS analysis indicated near-complete conversion to the 
product. The solution was filtered and purified by reverse 
phase-HPLC with a semi-preparative column (C18 column, 
Gemini, 5 µm, 10 × 250 mm; Phenomenex) at a flow rate 
of 5.0 ml/min; solvent A: 0.1% TFA in H2O, solvent B: 0.1% 
TFA in CH3CN. (G)3-DFO-azide eluted at 60–65% solvent 
B. Fractions containing pure product were collected and ly-
ophilized. LC-MS calculated for C65H115N18O24S [M+H]+ 
1,563.80, found 1,563.77.
Preparing 89Zr-labeled VHHs
The radiolabeling was performed following an established 
procedure (Vosjan et al., 2010). In a typical reaction, a solu-
tion of 0.5–2.0 mg of chelexed VHH-DFO or PEGylat-
ed-VHH-DFO in 200 µl of 0.5 M HEP ES buffer, pH 7.5 
was prepared. Then a volume of the 89Zr4+ stock solution 
(typically supplied in 1.0 M oxalic acid) corresponding to 1.0 
to 1.5 mCi was added to a 2 ml plastic screw-cap microcen-
trifuge tube. The volume of this solution was adjusted to a 
total of 300 µl using 1.0 M oxalic acid. The pH of the 89Zr4+ 
solution was adjusted to 6.8–7.5 using 2.0 M Na2CO3. This 
solution was added to VHH-DFO or PEG-VHH-DFO. The 
reaction mixture was incubated for 60 min at room tempera-
ture on an agitating block at 350 rpm, loaded onto a PD-10 
size-exclusion cartridge (GE Healthcare), and eluted with 1× 
PBS, yielding >80% (∼0.8–1.3 mCi) of 89Zr-VHH or PEG-
VHH (decay-corrected radiochemical yield).
PEt experiments and image analysis
PET-CT procedures have been described in detail elsewhere 
(Rashidian et al., 2015a). For imaging experiments, mice were 
anaesthetized using 2.0% isoflurane in O2 at a flow rate of ∼1 
liter per minute. Mice were imaged by PET-CT using a G8 
PET-CT small-animal scanner (PerkinElmer). Peak sensitivity 
of the G8 PET-CT accounts for >14% of positron emission, 
with a mean resolution of 1.4 mm. Each PET acquisition 
took 10 min, followed by a 1.5-min CT scan. Images were 
processed using the manufacturer’s automatic image recon-
struction software. Data were further analyzed and quantified 
using VivoQuant software. 2D and 3D visualizations were 
produced using the DIC OM viewer (OsiriX Foundation). 
PET images were viewed side by side with the CT images in 
DIC OM viewer software. Scans were sliced along the coronal 
plane. A representative image slice that best demonstrated the 
characteristics of immune cell infiltration for that particular 
sample was exported as a single DIC OM file. Cartesian points 
that framed the tumor were recorded. The DIC OM file was 
imported into MAT LAB and processed with code that read 
the DIC OM file and generated a matrix with PET signal 
values corresponding to each voxel. The Cartesian points re-
corded were used to crop the matrix to the tumor section 
only. 3D shaded surface plots were generated using the MAT 
LAB function surf, where the x and y axes represent points on 
the image plane and the z axis represents the PET signal value.
For PET quantification, PET images were imported 
into VivoQuant software. PET signal values were converted 
into units of percentage of injected dose per gram by using 
as input the radioactivity at the time of measurement with 
the preprocessing tool. The CT scan overlaid with PET signal 
was used as a guide to generate 3D regions of interest (ROIs) 
to represent a certain organ within the mouse. Depending 
on the complexity of the ROI, drawing the ROIs was either 
done free-hand or in automated fashion by setting a threshold 
value, such that it would capture all connected points with a 
PET signal above the threshold value. Once all ROIs were 
generated, a table was exported containing statistical infor-
mation, such as mean PET signal or variation, for each of 
ROIs. Clusters of CD8 T cells throughout the tumors were 
identified by connected voxels, and borders of each cluster 
were defined as the point at which the derivative of the PET 
signals became zero (saddle points or local minimums).
To identify local minima and maxima of PET signal 
within a tumor, we used the same representative image slice 
used to generate the surface plot mentioned previously. We 
chose three line segments that intersected the middle of the 
tumor and used MAT LAB to plot the signal intensity along 
the line segment. With the resulting plot, we approximated 
the first derivative by calculating the difference between adja-
cent values of signal intensity versus position on the line seg-
ment. A first derivative plot that crossed the x axis only once 
shows a single local maximum of the PET signal. In contrast, 
a plot that crossed the x axis two or more times indicates that 
the PET signal contained multiple local maxima or minima.
Immunohistochemistry
Immunohistochemistry was performed on 5-μm-thick sec-
tions deparaffinized to water. Antigen retrieval was done 
using DIVA solution (Biocare Medical). Endogenous enzyme 
was blocked for 5 min, and then mouse CD8 (14–0808-80; 
eBioscience) was incubated at 1:50 in TBS/BSA overnight at 
4°C. The following day, HRP rat probe (Rat Probe and Poly-
mer Kit; Biocare Medical) was incubated with the sections for 
20 min followed by HRP rat polymer, developed with DAB 
for 5 min, and then counterstained with hematoxylin.
Mammary tumor models
MMTV-PyMT PB2 and PB3 cells were a gift from the 
laboratory of H.L. Moses (Vanderbilt-Ingram Cancer Cen-
ter, Nashville, TN), where they were originally derived by 
A. Chytil essentially as described previously (Forrester et 
al., 2005). In brief, MMTV-PyMT mammary tumors from 
C57BL/6 mice were digested at 37°C for 4 h in serum-free 
DMEM/F12 + penicillin-streptomycin, amphotericin B, 
gentamicin, 2 mg/ml collagenase, and 100 U/ml hyaluroni-
dase. Cells were washed with PBS containing 5% adult bovine 
serum, plated in flasks coated with 50 µg/ml type I collagen, 
and then maintained in DMEM/F12 medium containing 2% 
adult bovine serum until they adapted to culture. Cells were 
adapted to DMEM/F12 medium containing 5% adult bovine 
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serum with penicillin-streptomycin and nonessential amino 
acids for the duration of this study.
online supplemental material
Fig. S1 shows a characterization of VHH-X118. Fig. S2 shows 
a characterization of PEGylated VHH. Fig. S3 shows PET 
images of an OT-I RAG-KO mouse. Fig. S4 shows the dy-
namics of CD8 T cell response and characterization of re-
sponse patterns to immunotherapy and survival. Fig. S5 shows 
hematoxylin and eosin staining and immunohistochem-
istry (CD8+ cells) of tumor samples. Videos 1, 2, 3, 4, and 
5 show that 89Zr-VHH-X118, 89Zr-PEG5-VHH-X118, 
89Zr-PEG10-VHH-X118, 89Zr-PEG20-VHH-X118, and 
89Zr-PEG20-VHH-X118 detect lymphoid organs. Video 6 
shows 89Zr-PEG20-VHH-X118 injected into a RAG-KO 
mouse. Video 7 shows that 89Zr-PEG20-VHH-X118 detects 
lymphoid organs in OT1-RAG KO mouse. Video  8 shows 
that 89Zr-PEG5-VHH-X118 detects lymphoid organs and 
the B16 tumor. Videos 9 and 10 show that 89Zr-PEG5-
VHH-X118 detects lymphoid organs and the Panc02 tumor.
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